Condition
Mucopolysaccharidosis Type IH
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Withdrawn1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04284254Phase 1Withdrawn
MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT
NCT01572636TerminatedPrimary
Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome
Showing all 2 trials